Phosphodiesterase type 5 inhibitor therapy: identifying and exploring what attributes matter more to clinicians and patients in the management of erectile dysfunction

被引:8
|
作者
Axilrod, Andrew C. [1 ]
机构
[1] Hosp Univ Penn, Div Urol, Philadelphia, PA 19104 USA
关键词
Comorbidities; erectile dysfunction; erection; first-dose success; PDE5; inhibitors; vardenafil;
D O I
10.1185/030079907X242656
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Erectile dysfunction (ED) is increasingly being recognized as a sentinel marker of future subsequent cardiovascular disease (CVD). Predicted increases in the prevalence of ED are due to a combination of an aging population and the increasing presence of comorbid conditions (hypertension, dyslipidemia, and diabetes). The dichotomy of the situation is that ED is often associated with these comorbidities, potentially leading to greater CVD risk, and conversely, these comorbidities have also been shown to increase the risk of developing ED. The successful treatment of ED with phosphodiesterase type 5 (PDE5) inhibitor therapy, therefore, is of paramount importance because it not only plays a critical role in restoring erectile function, but also provides clinicians with the opportunity to mitigate existing cardiovascular comorbidities or prevent the occurrence of CVD in this patient population. Methods:This review is based on an electronic literature search of databases, including MEDLINE/PubMed, with information selected for its relevance to PDE5 inhibitor therapy comprising efficacy (e.g., first-dose success) in men with ED with or without comorbidities, onset and duration of action at specific time points, and patient preference. Results: The introduction of PDE5 inhibitors represented a major advance in the treatment of ED. In spite of the availability of these agents, a large percentage of men are still not being treated, in many cases because of their reluctance to seek medical help. Moreover, many men who start treatment with PDE5 inhibitors discontinue treatment. Reasons for discontinuation are many and complex, including lack of initial or first-time success. Although of major concern to both patients and clinicians, there remains limited published clinical data on this specific parameter in the pertinent patient population and from prospective, randomized clinical studies. Conclusion: Data from studies suggests that the available PDE5 inhibitor therapies are effective in treating men with ED, including those who have increased CVD risk and those who have clinically identified cardiovascular comorbidities such as hypertension, dyslipidemia, and/or diabetes. According to data from studies, the attributes of PDE5 inhibitor therapy that matter more to clinicians and patients and that hold influence over treatment compliance include effectiveness in patients with cardiovascular comorbidities, first dose effectiveness or early success, rapid onset of action, reliability, and tolerability.
引用
收藏
页码:3189 / 3198
页数:10
相关论文
共 50 条
  • [1] MEDICATION UTILIZATION IN PATIENTS RECEIVING PHOSPHODIESTERASE TYPE 5 INHIBITOR FOR ERECTILE DYSFUNCTION
    Mulhall, J. P.
    Chopra, I
    Patel, D.
    Tang, W. Y.
    Hassan, T. A.
    JOURNAL OF SEXUAL MEDICINE, 2018, 15 (07): : S370 - S370
  • [2] Non-invasive management of primary phosphodiesterase type 5 inhibitor failure in patients with erectile dysfunction
    Lowe, Gregory
    Bahnson, Robert
    THERAPEUTIC ADVANCES IN UROLOGY, 2009, 1 (05) : 235 - 242
  • [3] Erectile dysfunction : Treatment with inhibitor drugs of type 5 phosphodiesterase
    不详
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2007, 53 (02): : 102 - 103
  • [4] Predictors of Phosphodiesterase Type 5 Inhibitor Treatment Failure in Patients Diagnosed With Erectile Dysfunction
    Albarakati, Muath
    El-Tholoth, Hossam S.
    Alzahrani, Abdulaziz
    Alghamdi, Omar S.
    Alquliti, Abdulrahman
    Alnuami, Musa
    Althobity, Abdalmagid
    Almardawi, Abdulmalik
    Bedaiwi, Khaled
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (12)
  • [5] New phosphodiesterase type 5 inhibitors in the management of erectile dysfunction
    Mason, RG
    JOURNAL OF THE ROYAL SOCIETY FOR THE PROMOTION OF HEALTH, 2003, 123 (02): : 79 - 80
  • [6] Chronic Low Dosing of Phosphodiesterase Type 5 Inhibitor for Erectile Dysfunction
    Sung, Hyun Hwan
    Lee, Sung Won
    KOREAN JOURNAL OF UROLOGY, 2012, 53 (06) : 377 - 385
  • [7] The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction
    Paick, Jae-Seung
    Kim, Sae Woong
    Yang, Dae Yeol
    Kim, Ja Jong
    Lee, Sung Won
    Ahn, Tai Young
    Choi, Hyung Ki
    Suh, Jun-Kyu
    Kim, Sae Chul
    JOURNAL OF SEXUAL MEDICINE, 2008, 5 (04): : 946 - 953
  • [8] Non-invasive Management Options for Erectile Dysfunction When a Phosphodiesterase Type 5 Inhibitor Fails
    Mary Lee
    Roohollah Sharifi
    Drugs & Aging, 2018, 35 : 175 - 187
  • [9] Non-invasive Management Options for Erectile Dysfunction When a Phosphodiesterase Type 5 Inhibitor Fails
    Lee, Mary
    Sharifi, Roohollah
    DRUGS & AGING, 2018, 35 (03) : 175 - 187
  • [10] Phosphodiesterase Type 5 Inhibitor and Erectile Dysfunction in Lower Urinary Tract Symptoms
    Zhao, Chen
    Park, Jong Kwan
    LUTS-LOWER URINARY TRACT SYMPTOMS, 2012, 4 : 75 - 80